Platelet Rich Plasma Therapy Explained: The Blood Science Behind Why Not All PRP Is Created Equal

Introduction: Why ‘PRP’ Means Something Different at Every Clinic

Consider two patients, both seeking relief from persistent knee pain. Both receive what their respective clinics call “PRP therapy.” One patient experiences significant improvement within weeks. The other notices little change at all. Same treatment name, vastly different results.

This scenario plays out across clinics nationwide, and the explanation lies in a critical truth that most patients never learn: platelet rich plasma therapy explained in marketing materials rarely captures the biological complexity that determines success or failure. PRP is not a single standardized therapy. It is a family of related blood-derived preparations whose composition varies significantly based on how each clinic prepares it.

In plain terms, PRP is a concentrated solution made from a patient’s own blood, designed to accelerate healing and tissue repair. The concept sounds straightforward. The reality is far more nuanced.

This article examines the science behind PRP, the critical classification split between LP-PRP and LR-PRP that most patients never hear about, what the preparation process actually involves, which conditions benefit from which type, and how patients can use this knowledge to evaluate provider quality. The information draws on 2025 and 2026 peer-reviewed research and clinical data to provide a comprehensive understanding of why not all PRP is created equal.

What Is Platelet Rich Plasma? The Biology in Plain Language

Understanding PRP requires a brief tour of blood composition. Blood contains four main components: red blood cells (which carry oxygen), white blood cells or leukocytes (the immune system’s soldiers), platelets (small disc-shaped cell fragments), and plasma (the liquid that carries everything).

Platelets deserve particular attention. While most people associate them with blood clotting, platelets are biological first responders that do far more than stop bleeding. They initiate tissue repair by releasing a cascade of healing signals.

What makes PRP “rich” is concentration. Normal blood contains roughly 150,000 to 400,000 platelets per microliter. PRP is defined as plasma containing at least 200,000 platelets per microliter, typically representing a two to five fold increase over baseline. Some protocols achieve up to ten fold concentration.

The therapeutic power of PRP lies within alpha-granules, storage compartments inside each platelet that release growth factors when activated. The key players include:

PDGF (Platelet-Derived Growth Factor) stimulates cell growth and division. VEGF (Vascular Endothelial Growth Factor) promotes new blood vessel formation. TGF-β (Transforming Growth Factor-beta) regulates tissue remodeling. IGF (Insulin-Like Growth Factor) supports cell survival and repair.

Think of platelets as the body’s repair crew. PRP is like calling in a much larger crew to a specific injury site, equipped with concentrated supplies of healing materials.

Because PRP comes from the patient’s own blood (making it autologous), the risk of allergic reaction or immune rejection is dramatically reduced compared to treatments using donor materials.

How PRP Is Made: A Step-by-Step Look at the Preparation Process

The preparation process is not merely a technicality. It is where the quality of the final product is determined, and where clinics differ most significantly. Understanding these steps gives patients valuable insight into what separates high-quality treatment from generic protocols.

Step 1: The Blood Draw

A standard blood draw of 20 to 60 mL is taken from the patient’s arm, roughly two to four tablespoons. An anticoagulant such as sodium citrate or ACD-A is added to prevent premature clotting. The specific anticoagulant used is one variable that affects the final PRP composition.

Patient preparation matters at this stage. Hydration levels, recent NSAID or anticoagulant use, and baseline platelet count all influence blood quality and therefore PRP quality. Even needle gauge and collection technique play roles that experienced providers account for.

Step 2: Centrifugation, Where the Separation Happens

The blood sample enters a centrifuge machine that spins at high speed, using centrifugal force to separate components by density. Three distinct layers form: platelet-poor plasma (PPP) rises to the top, the platelet-rich “buffy coat” settles in the middle, and red blood cells sink to the bottom.

The distinction between single-spin and double-spin protocols is crucial. A single spin produces basic separation. The double-spin method, which is the most widely recommended protocol, uses a first “soft spin” to separate red blood cells from plasma, followed by a second “hard spin” to further concentrate platelets. The entire double-spin process takes approximately 12 minutes.

Spin speed (RPM), duration, temperature, and number of spins all directly determine platelet concentration and leukocyte content in the final product. This is the key quality control point: two clinics using the same “PRP” label may produce biologically very different products based solely on their centrifugation protocol.

Step 3: Extraction and Injection

After centrifugation, the technician or physician extracts the platelet-rich layer using a syringe. The PRP may be “activated” using calcium chloride or thrombin to trigger platelet degranulation (the release of growth factors) before injection. Activated versus non-activated PRP represents another variable affecting outcomes.

The PRP is then injected into the target tissue. Ideally, imaging guidance using ultrasound or X-ray ensures precise delivery. Imaging-guided injection is a significant quality differentiator; blind injections risk missing the target tissue entirely.

The entire process from blood draw to injection can be completed in a single appointment.

The Classification Split That Changes Everything: LP-PRP vs. LR-PRP

This distinction is the most important variable for predicting outcomes, yet most patient-facing content never covers it.

PRP is classified into two primary types based on leukocyte (white blood cell) content: Leukocyte-Poor PRP (LP-PRP) and Leukocyte-Rich PRP (LR-PRP).

Leukocytes matter because white blood cells are the immune system’s inflammatory agents. Their presence in PRP amplifies the inflammatory response at the injection site. This can be beneficial or harmful depending on the condition being treated.

Consider this analogy: leukocytes in PRP are like adding fuel to a fire. Sometimes more heat accelerates healing (for certain tendon injuries). Sometimes more heat causes damage (in already-inflamed joints).

Leukocyte-Poor PRP (LP-PRP): The Anti-Inflammatory Option

LP-PRP is processed to remove most white blood cells, producing a preparation with high platelet concentration but minimal leukocyte content. The lower inflammatory profile makes LP-PRP the preferred choice for intra-articular (joint) injections, particularly for osteoarthritis.

Clinical evidence supports this approach. A 2025 narrative review of 40 high-quality studies found LP-PRP demonstrates superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids for knee osteoarthritis, especially in mild-to-moderate cases (Kellgren-Lawrence grades I through III).

Why does this matter for joints? Cartilage is avascular (has no blood supply) and highly sensitive to inflammation. Introducing leukocyte-rich preparations into a joint can worsen the inflammatory environment and accelerate cartilage degradation. LP-PRP is also associated with less post-injection pain flare compared to LR-PRP.

Leukocyte-Rich PRP (LR-PRP): The Inflammatory Boost Option

LR-PRP retains a high concentration of white blood cells alongside concentrated platelets. The elevated inflammatory signaling may benefit tendinopathies (tendon injuries) and certain soft tissue conditions where the body’s natural healing response is insufficient or has stalled.

The rationale: chronic tendinopathy is often characterized by a failed healing response. The tissue is not actively inflamed enough to trigger repair. LR-PRP’s pro-inflammatory profile may “restart” the healing cascade. LR-PRP also has antimicrobial properties due to leukocyte activity, which may be relevant in wound care applications.

However, LR-PRP is generally not recommended for joint injections due to the risk of exacerbating synovial inflammation.

Why This Classification Matters for Patients: The Questions to Ask

Knowing this classification exists gives patients vocabulary to evaluate provider quality. Suggested questions for any PRP provider include:

• “What type of PRP do you prepare, leukocyte-poor or leukocyte-rich?”
• “What centrifugation protocol do you use?”
• “Do you use imaging guidance for the injection?”
• “Will the PRP be activated before injection?”

A provider who cannot answer these questions, or who treats all PRP as interchangeable, represents a red flag. The lack of standardized preparation protocols across the industry is a recognized challenge, with variables including centrifuge speed, number of spins, anticoagulant type, leukocyte content, and platelet concentration all significantly affecting clinical outcomes.

What Conditions Can PRP Treat? A Condition-by-Condition Breakdown

PRP is not a cure-all. It is most effective for specific conditions at specific stages of severity. The LP-PRP versus LR-PRP classification helps determine the appropriate match.

Orthopedic Conditions: Joints, Tendons, and Ligaments

Knee osteoarthritis: LP-PRP is the evidence-supported choice, most effective for mild-to-moderate cases. A 2025 meta-analysis found PRP produced statistically significant large pain reduction (SMD = -0.83) compared to placebo and outperformed corticosteroids and hyaluronic acid.

Tendinopathies (tennis elbow, Achilles tendinopathy, rotator cuff tendinopathy): LR-PRP may be more appropriate due to its pro-inflammatory, healing-stimulating properties. Learn more about PRP as a game-changer for tendon injuries.

Ligament and muscle injuries: PRP accelerates healing; evidence is growing but more variable.

Plantar fasciitis: PRP shows promising results as an alternative to corticosteroid injections, which can weaken tissue with repeated use.

Rotator cuff injuries and meniscus conditions: Used as adjuncts to conservative care or post-surgical healing.

Notably, Tricare offers provisional coverage for chronic mild-to-moderate knee osteoarthritis and lateral epicondylitis, representing one of the few insurance exceptions.

Dermatology and Hair Restoration

Androgenetic alopecia (pattern hair loss): PRP injected into the scalp stimulates dormant hair follicles. A 2025 meta-analysis of 43 RCTs (1,877 participants) found activated PRP effective in increasing hair density and minimizing recurrence compared to placebo.

Results timelines differ from joint injections. Scalp PRP results may take up to six months and require multiple sessions.

Skin rejuvenation: PRP combined with microneedling (sometimes called the “vampire facial”) addresses skin texture, tone, and scar remodeling. Growth factors stimulate collagen production.

Wound care: PRP is used in chronic wound management, including diabetic ulcers. Medicare provides coverage for chronic non-healing diabetic wounds for up to 20 weeks.

Emerging Frontiers: Reproductive Medicine and Beyond

Intraovarian PRP: An emerging application for women with diminished ovarian reserve or premature ovarian insufficiency. PRP injected directly into the ovaries may stimulate local stem cells, promote neoangiogenesis, and potentially reawaken dormant follicles. A 2025 Nature Scientific Reports study found intraovarian PRP significantly improved blastocyst yield and quality in IVF patients with poor ovarian response.

Endometrial repair and vulvovaginal atrophy: PRP is being investigated for uterine lining repair and gynecological applications.

Ophthalmology: Emerging research explores PRP for ocular surface conditions.

These applications are at earlier stages of evidence than orthopedic uses. Patients should seek providers with specific expertise in these areas.

The Science Is Still Evolving: What New Research Reveals About How PRP Works

Recent 2025 and 2026 research has uncovered mechanisms beyond the standard growth factor explanation.

Mitochondrial transfer: Platelets can transfer mitochondria (the cell’s energy-producing organelles) to damaged target cells, potentially restoring cellular energy metabolism in injured tissue.

MicroRNA delivery: Platelets deliver bioactive microRNAs that regulate inflammation and metabolic reprogramming at the cellular level.

These discoveries suggest PRP’s healing mechanisms are more sophisticated than previously understood. Optimizing preparation protocols to preserve these components may prove important.

The global PRP market reflects growing clinical confidence, valued at approximately $513.7 million in 2025 and projected to reach $1.39 billion by 2034 at an 11.3% CAGR. North America holds the dominant global market share, with orthopedic surgery accounting for approximately 30 to 45 percent of all PRP applications.

What Affects PRP Quality: Patient-Specific Factors

The patient is a variable in PRP quality, not just the clinic’s protocol.

Age: Platelet count and function naturally decline with age, affecting the growth factor payload.

Comorbidities: Diabetes, autoimmune disorders, or chronic inflammatory diseases can affect platelet function and the healing environment.

Medications: NSAIDs and anticoagulants directly interfere with platelet function. Patients are typically advised to stop NSAIDs one to two weeks before treatment.

Hydration: Adequate hydration before the blood draw improves blood volume and collection ease.

Lifestyle factors: Smoking, poor nutrition, and sedentary lifestyle can negatively affect platelet quality.

Baseline platelet count: Patients with naturally lower counts may produce less concentrated PRP. Some providers check a baseline CBC before proceeding.

Patients should discuss their full medication list and health history with their provider and follow pre-procedure preparation instructions carefully.

What to Expect: Before, During, and After PRP Treatment

Before the Procedure

Patients should stop NSAIDs and anti-inflammatory medications as directed (typically one to two weeks before). Staying well hydrated is important. Providers should be informed of all medications, supplements (especially fish oil, vitamin E, and aspirin), and recent illnesses. Fasting is generally not required, but patients should confirm with their provider. Loose, comfortable clothing with easy arm access is recommended.

During the Procedure

The blood draw takes a few minutes; centrifugation takes approximately 12 minutes for a double-spin protocol. For joint injections, imaging guidance should confirm accurate needle placement. Local anesthetic may minimize discomfort. The entire appointment typically takes 45 to 90 minutes. For a detailed walkthrough, see our PRP injection procedure step-by-step guide.

After the Procedure: Recovery and Results Timeline

A temporary pain flare in the first one to two weeks is expected. This normal inflammatory response does not mean treatment is failing. Strenuous activity should be avoided for approximately 72 hours. NSAIDs should continue to be avoided after injection. Results timelines vary: joint injection benefits are typically noticeable after several weeks, while hair loss treatment results may take up to six months. Results are not permanent, and repeat injections are often needed. Common side effects are mild, including temporary soreness and bruising at the injection site.

Safety, Contraindications, and Who Should Not Receive PRP

PRP is considered low-risk because it uses the patient’s own blood, dramatically reducing the risk of allergic reaction or immune rejection. Studies show no different incidence of infection or nerve injuries compared to cortisone injections.

Contraindications include: active infections at or near the injection site; active cancer or history of certain blood cancers; platelet dysfunction disorders or thrombocytopenia; anticoagulant therapy (medication may need to be paused with prescribing physician guidance); severe anemia; and pregnancy for certain applications.

Full medical disclosure allows providers to assess candidacy appropriately. Being low-risk and being appropriate for everyone are different statements.

The Regulatory and Insurance Reality: What Patients Need to Know

As of 2026, the FDA has not approved PRP as a treatment for most clinical indications. The FDA has cleared the devices (centrifuges, collection kits) used to produce PRP, but PRP is used off-label for most orthopedic, dermatological, and other applications, which is legal and common in medicine.

The narrow Medicare exception: CMS covers PRP for chronic non-healing diabetic wounds for up to 20 weeks when prepared by FDA-cleared devices. Tricare offers provisional coverage for chronic mild-to-moderate knee osteoarthritis and lateral epicondylitis.

Most major insurance carriers classify PRP as experimental. Out-of-pocket costs typically range from $500 to $2,500 per session, with many conditions requiring multiple sessions.

Patients should verify specific coverage and ask providers for transparent pricing before committing. The regulatory landscape is evolving; as more Phase III clinical trial data emerges (including a $140 million trial announced in January 2026), coverage decisions may change.

How to Evaluate a PRP Provider: A Patient’s Checklist

The science translates into actionable evaluation criteria:

Protocol transparency: Does the provider specify LP-PRP or LR-PRP and explain why that choice fits the condition?

Centrifugation method: Do they use a double-spin protocol? What centrifuge system?

Imaging guidance: Are injections performed under ultrasound-guided PRP injection or fluoroscopic guidance?

Activation protocol: Do they activate PRP before injection based on the condition?

Patient assessment: Does the provider review medications, health history, and baseline platelet status?

Realistic expectations: Does the provider give honest timelines and discuss the likelihood of repeat treatments?

Credentials and experience: Is the injection performed by a physician or appropriately credentialed provider with specific regenerative medicine training?

Red flags: Providers who cannot explain their protocol, offer PRP as a guaranteed cure, or do not discuss contraindications.

Providers like Unicorn Bioscience emphasize personalized treatment planning based on individual factors including inflammation levels, age, injury type, and current medications, with imaging-guided injections delivered using advanced ultrasound and X-ray technology. This approach reflects the protocol transparency patients should expect.

Conclusion: PRP Is a Family of Therapies, Not a Single Treatment

The reason PRP produces different results at different clinics is not random. It is a direct consequence of preparation protocol, leukocyte classification, and patient-specific factors.

Key takeaways: PRP is a concentrated blood-derived preparation rich in growth factors. The LP-PRP versus LR-PRP distinction is the most clinically important variable for matching treatment to condition. The centrifugation protocol determines the biological composition of the final product. Patient factors including age, medications, and health status influence outcomes.

Understanding these distinctions gives patients vocabulary to ask better questions and evaluate provider quality, not just treatment availability.

The science continues evolving. Research in 2025 and 2026 reveals new mechanisms (mitochondrial transfer, microRNA delivery) and new applications (reproductive medicine, ophthalmology), making PRP one of the most actively researched areas in regenerative medicine. As standardization improves and clinical trial data matures, PRP’s role in medicine is likely to expand. Patients who understand the science will be best positioned to benefit.

Ready to Learn If PRP Is Right for You? Talk to a Specialist

For patients who want to take the next step, a personalized consultation with a provider who can assess a specific condition, health history, and goals is the appropriate path forward.

Unicorn Bioscience offers personalized treatment planning based on individual factors including inflammation levels, age, injury type, and current medications, with imaging-guided injections and a multi-modality treatment menu. Virtual and in-person consultations are available across eight locations in Texas, Florida, and New York, with same-day treatment available for qualified candidates.

Schedule a consultation with the team at Unicorn Bioscience to discuss whether PRP, and which type of PRP, may be appropriate for a specific condition. Visit unicornbioscience.com or call (737) 347-0446.

Patients who come in informed get more productive consultations and better outcomes. This article provides the foundation to have that conversation.